Medicare Part D Coverage Determination and Redetermination Appeals: What Your Practice Needs to Know for July 2026

If you've ever watched a patient walk away from the pharmacy counter without their medication because of a coverage denial — and then spent the next two hours trying to figure out what just happened — you already understand why mastering the Part D appeals process matters. Medicare Part D coverage determinations and redeterminations are a consistent pain point for practices, and with CMS continuing to refine its policies heading into mid-2026, there's never been a better time to make sure your team actually knows the process cold. Not the vague outline of it. The real, step-by-step, what-do-I-do-Monday-morning version.

Understanding Coverage Determinations: The First Decision That Sets Everything in Motion

A coverage determination is simply the first official decision a Part D plan makes about whether it will cover a drug, how much the beneficiary will pay, or whether an exception applies. Think of it as the starting line. Everything else — appeals, grievances, escalations — flows from this moment.

There are a few different types of coverage determinations your patients might encounter:

• Formulary exceptions – the drug isn't on the plan's formulary, but you're requesting it anyway based on medical necessity


• Tiering exceptions – the drug is covered, but at a higher cost-sharing tier, and you want it moved down


• Prior authorization requests – the plan requires approval before they'll cover the drug


• Step therapy exceptions – the plan wants the patient to try a different (usually cheaper) drug first

Here's something a lot of billing staff don't fully appreciate: you can request an expedited determination when the standard 72-hour timeframe would seriously jeopardize the patient's health or life. For expedited cases, plans must respond within 24 hours. Don't wait for a patient to hit crisis mode before you know this option exists — build it into your workflows now.

One practical note: as of 2026, CMS has increased its scrutiny of plans that routinely delay or improperly deny coverage determinations. If a plan misses the decision deadline, that's actually considered an adverse determination and the patient can appeal immediately. Worth knowing.

The Redetermination Process: Your First Real Bite at the Apple

If the initial coverage determination goes against your patient, the next step is a redetermination — essentially asking the plan to take another look. This is Level 1 of the five-level Medicare Part D appeals process, and it's where a lot of practices either win their cases or fumble them unnecessarily.

A few critical things to get right here:

Timing matters. Patients (or their prescribers) have 60 days from the date of the adverse determination to file a redetermination request. That clock starts ticking the moment the denial goes out — not when the patient calls your office to tell you about it.

Who can file. The enrollee, their representative, or the prescriber can all file a redetermination. As a prescriber or practice, you can file on the patient's behalf, which often moves things faster because you can speak directly to medical necessity.

What to include. This is where most appeals live or die. A strong redetermination request isn't just a cover letter saying "we disagree." Include:

• A clear clinical narrative explaining why this specific drug is medically necessary for this specific patient


• Relevant clinical notes, labs, or diagnostic records


• Documentation of why alternatives are inappropriate (formulary alternatives tried, failed, or contraindicated)


• Any applicable clinical guidelines or literature

Real talk: I've seen appeals fail not because the clinical case was weak, but because the supporting documentation was a vague two-sentence letter. Plans aren't in the business of filling in the blanks for you. Give them everything they need to say yes.

Plans have 7 calendar days for standard redeterminations and 72 hours for expedited ones. If they don't respond in time, the case automatically escalates to Level 2 — the Independent Review Entity (IRE).

Navigating Levels 2 Through 5: When the Plan Says No (Again)

Most appeals get resolved at Levels 1 or 2. But it helps to know what you're walking into if they don't.

Level 2 – Independent Review Entity (IRE): A CMS-contracted organization reviews the case independently. For 2026, Maximus Federal Services continues in this role. You have 60 days from the Level 1 denial to file here. The IRE has the same timeframes as the plan: 7 days standard, 72 hours expedited.

Level 3 – Office of Medicare Hearings and Appeals (OMHA): Here's where it gets more formal. An administrative law judge reviews the case. The amount in controversy must meet a minimum threshold (adjusted annually for inflation — check the 2026 figure, as it's typically around $200 for Part D). This level can take months, but it's worth pursuing for high-cost medications where the clinical case is strong.

Levels 4 and 5 involve the Medicare Appeals Council and federal district court, respectively. These are relatively rare but are legitimate options when the stakes are high enough — think expensive specialty drugs or biologics.

One thing practices often forget: keep meticulous records of every step. Dates, denial letters, submission confirmations, everything. If a case escalates, your documentation trail is what keeps it moving.

Practical Workflow Tips Your Team Can Implement Now

You don't need to overhaul everything overnight. Here are some changes that actually make a difference:

• Create a denial tracker. A simple spreadsheet tracking every Part D denial by patient, drug, date, and appeal status will surface patterns — like a particular plan that's denying a specific drug repeatedly, which may signal a formulary issue worth escalating differently.


• Template your appeal letters. Not generic templates — condition-specific ones that include the right clinical framing for diabetes, oncology, mental health, etc. Update them quarterly as formularies change.


• Train front desk and MA staff to flag Part D denials immediately rather than letting them sit in a patient message queue for three days. Timing kills more appeals than bad documentation.


• Use AI-powered appeal generators thoughtfully. Tools that help draft appeal letters using patient-specific clinical data exist and can meaningfully cut down the time your staff spends on documentation — but always have a clinician review the final output. These tools work best when your team still understands the underlying process.


• Know your plan contacts. Each Part D plan has a provider services line. Building relationships with those representatives — or at least knowing the number — can sometimes resolve issues before they become formal appeals.

Conclusion: Don't Let the Process Win by Default

The Part D appeals process can feel like it's designed to wear you down. And honestly, sometimes it is. Plans count on the fact that busy practices will give up after a first denial. Don't.

Your next steps heading into July 2026:

• Audit your current appeal success rate by plan and drug — if you don't know it, you can't improve it


• Refresh your appeal templates using the documentation guidelines above


• Make sure every prescriber in your practice knows the expedited determination option exists and when to use it


• Schedule a 30-minute team refresher on the five-level appeals process — it doesn't take long and it closes a lot of gaps

Your patients are counting on you to know this process better than the plans do. And increasingly, the ones who do win more often.

---

Tags: pharmacy, Part D, coverage determination, redetermination, Medicare